Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias
Open Access
- 4 September 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 11
Abstract
Diseases of the heart, such as heart failure and cardiac arrhythmias, are a growing socio-economic burden. Calcium (Ca2+) dysregulation is key hallmark of the failing myocardium and has long been touted as a potential therapeutic target in the treatment of a variety of cardiovascular diseases (CVD). In the heart, Ca2+ is essential for maintaining normal cardiac function through the generation of the cardiac action potential and its involvement in excitation contraction coupling. As such, the proteins which regulate Ca2+ cycling and signaling play a vital role in maintaining Ca2+ homeostasis. Changes to the expression levels and function of Ca2+-channels, pumps and associated intracellular handling proteins contribute to altered Ca2+ homeostasis in CVD. The remodeling of Ca2+-handling proteins therefore results in impaired Ca2+ cycling, Ca2+ leak from the sarcoplasmic reticulum and reduced Ca2+ clearance, all of which contributes to increased intracellular Ca2+. Currently, approved treatments for targeting Ca2+ handling dysfunction in CVD are focused on Ca2+ channel blockers. However, whilst Ca2+ channel blockers have been successful in the treatment of some arrhythmic disorders, they are not universally prescribed to heart failure patients owing to their ability to depress cardiac function. Despite the progress in CVD treatments, there remains a clear need for novel therapeutic approaches which are able to reverse pathophysiology associated with heart failure and arrhythmias. Given that heart failure and cardiac arrhythmias are closely associated with altered Ca2+ homeostasis, this review will address the molecular changes to proteins associated with both Ca2+-handling and -signaling; their potential as novel therapeutic targets will be discussed in the context of pre-clinical and, where available, clinical data.Keywords
Funding Information
- British Heart Foundation
- Medical Research Council
This publication has 341 references indexed in Scilit:
- CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardiaCell Death & Disease, 2013
- Evidence for functional expression of TRPM7 channels in human atrial myocytesBasic Research in Cardiology, 2012
- Sodium Accumulation in SERCA Knockout-Induced Heart FailureBiophysical Journal, 2012
- Overview of Basic Mechanisms of Cardiac ArrhythmiaCardiac Electrophysiology Clinics, 2011
- Early afterdepolarizations and cardiac arrhythmiasHeart Rhythm, 2010
- Fixing ryanodine receptor Ca2+ leak – a novel therapeutic strategy for contractile failure in heart and skeletal muscleDrug Discovery Today: Disease Mechanisms, 2010
- S100A1 in cardiovascular health and disease: Closing the gap between basic science and clinical therapyJournal of Molecular and Cellular Cardiology, 2009
- Dantrolene, a Therapeutic Agent for Malignant Hyperthermia, Markedly Improves the Function of Failing Cardiomyocytes by Stabilizing Interdomain Interactions Within the Ryanodine ReceptorJACC, 2009
- Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical TrialJournal of Cardiac Failure, 2009
- The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmiasHeart Rhythm, 2008